Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy.

Journal for immunotherapy of cancer - 1 Mar 2021

Guo Xuan, Mahlakõiv Tanel, Ye Qian, Somanchi Srinivas, He Shuyang, Rana Hemlata, DiFiglia Andrea, Gleason Joseph, van der Touw William, Hariri Robert, Zhang Xiaokui

Abstract excerpt

BACKGROUND: Tumors often develop resistance to surveillance by endogenous immune cells, which include natural killer (NK) cells. Ex vivo activated and/or expanded NK cells demonstrate cytotoxicity against various tumor cells and are promising therapeutics for adoptive cancer immunotherapy. Genetic modification can further enhance NK effector cell activity or activation sensitization. Here, we evaluated the effect...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Clustered Regularly Interspaced Short Palindromic Repeats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Associated Protein 9

Share to HL-60 Cells

Share to Immunotherapy, Adoptive

Share to K562 Cells

Share to NK Cell Lectin-Like Receptor Subfamily C

Share to Proto-Oncogene Proteins c-cbl

Source

Open in PubMed Open full text

Identifiers

PMID: 33741730
DOI: 10.1136/jitc-2020-001975
PMCID: PMC7986888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy.PMID 33741730Read ↗

Applying CRISPR-based genetic screens to identify drivers of tumor-cell sensitivity towards NK-cell attackSemantic proximity Read ↗

Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 RibonucleoproteinsSemantic proximity Read ↗

Natural Born Killers: NK Cells in Cancer TherapySemantic proximity Read ↗

Perturbomics of tumor-infiltrating NK cellsSemantic proximity Read ↗

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer ImmunotherapySemantic proximity Read ↗

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 RibonucleoproteinsSemantic proximity Read ↗

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 RibonucleoproteinsSemantic proximity Read ↗

Genome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γSemantic proximity Read ↗

Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencySemantic proximity Read ↗

Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screeningSemantic proximity Read ↗

Surfaceome CRISPR activation screening uncovers ligands regulating tumor sensitivity to NK cell killingSemantic proximity Read ↗

CRISPR-Targeted CAR Gene Insertion Using Cas9/RNP and AAV6 Enhances Anti-AML Activity of Primary NK CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.